Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study.
BACKGROUND
The degree of pulmonary hypertension in healthy subjects exposed to acute hypobaric hypoxia at high altitude was found to be related to increased plasma endothelin (ET)-1. The aim of the present study was to investigate the effects of ET-1 antagonism on pulmonary hypertension, renal water, and sodium balance under acute and prolonged exposure to high-altitude-associated hypoxia.


RESULTS
In a double-blind fashion, healthy volunteers were randomly assigned to receive bosentan (62.5 mg for 1 day and 125 mg for the following 2 days; n=10) or placebo (n=10) at sea level and after rapid ascent to high altitude (4559 m). At sea level, bosentan did not induce any significant changes in hemodynamic or renal parameters. At altitude, bosentan induced a significant reduction of systolic pulmonary artery pressure (21+/-7 versus 31+/-7 mm Hg, P<0.03) and a mild increase in arterial oxygen saturation versus placebo after just 1 day of treatment. However, both urinary volume and free water clearance (H2OCl/glomerular filtration rate) were significantly reduced versus placebo after 2 days of ET-1 antagonism (1100+/-200 versus 1610+/-590 mL; -6.7+/-3.5 versus -1.8+/-4.8 mL/min, P<0.05 versus placebo for both). Sodium clearance and segmental tubular function were not significantly affected by bosentan administration.


CONCLUSIONS
The present results indicate that the early beneficial effect of ET-1 antagonism on pulmonary blood pressure is followed by an impairment in volume adaptation. These findings must be considered for the prevention and treatment of acute mountain sickness.
Modesti
Pietro Amedeo
PA
Clinica Medica Generale e Cardiologia, University of Florence, Viale Morgagni 85, 50134 Florence, Italy. pamodesti@unifi.it
Vanni
Simone
S
Morabito
Marco
M
Modesti
Alessandra
A
Marchetta
Matilde
M
Gamberi
Tania
T
Sofi
Francesco
F
Savia
Giulio
G
Mancia
Giuseppe
G
Gensini
Gian Franco
GF
Parati
Gianfranco
G
D000208:Acute Disease; D000222:Adaptation, Physiological; D000328:Adult; D000531:Altitude; D000532:Altitude Sickness / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D001127:Arginine Vasopressin / Q000037:antagonists & inhibitors; D000077300:Bosentan; D003404:Creatinine / Q000097:blood; D004231:Diuresis / Q000187:drug effects; D004311:Double-Blind Method; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000096:biosynthesis / Q000502:physiology* / Q000652:urine; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000503:physiopathology*; D000860:Hypoxia / Q000209:etiology / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D009994:Osmolar Concentration; D010100:Oxygen / Q000097:blood; D024642:Potassium Channels, Voltage-Gated / Q000502:physiology*; D011651:Pulmonary Artery / Q000503:physiopathology; D011654:Pulmonary Edema / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D017466:Receptors, Endothelin / Q000502:physiology; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014661:Vasoconstriction / Q000187:drug effects*
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D024642:Potassium Channels, Voltage-Gated; D017466:Receptors, Endothelin; D013449:Sulfonamides; D001127:Arginine Vasopressin; D003404:Creatinine; D000077300:Bosentan; D010100:Oxygen